ULTRAGENYX PHARMACEUTICAL INC. — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/e0ead587-78d8-4a93-8c7f-70264640ad1b/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $673.0M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-057329 |
| FY 2024 | $560.0M | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-057329 |
| FY 2023 | $434.0M | 2023-01-01 – 2023-12-31 | evidence 0001193125-26-057329 |
| FY 2022 | $363.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003096 |
| FY 2021 | $351.4M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-001284 |
| FY 2020 | $271.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-005610 |
| FY 2019 | $103.7M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-004667 |
| FY 2018 | $51.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003324 |
| FY 2017 | $2.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-003324 |
| FY 2016 | $133.0k | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-003324 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ULTRAGENYX PHARMACEUTICAL INC. — all facts · Net Income · Operating Income